X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TIMKEN INDIA with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TIMKEN INDIA vs INDOCO REMEDIES - Comparison Results

TIMKEN INDIA    Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TIMKEN INDIA INDOCO REMEDIES TIMKEN INDIA/
INDOCO REMEDIES
 
P/E (TTM) x 41.5 37.4 111.1% View Chart
P/BV x 6.0 2.9 206.1% View Chart
Dividend Yield % 0.2 0.8 20.8%  

Financials

 TIMKEN INDIA   INDOCO REMEDIES
EQUITY SHARE DATA
    TIMKEN INDIA
Mar-18
INDOCO REMEDIES
Mar-17
TIMKEN INDIA/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,008360 279.7%   
Low Rs630249 252.9%   
Sales per share (Unadj.) Rs181.5119.0 152.5%  
Earnings per share (Unadj.) Rs13.58.4 161.7%  
Cash flow per share (Unadj.) Rs19.915.2 130.5%  
Dividends per share (Unadj.) Rs1.001.60 62.5%  
Dividend yield (eoy) %0.10.5 23.3%  
Book value per share (Unadj.) Rs103.370.7 146.1%  
Shares outstanding (eoy) m68.0092.15 73.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.52.6 176.3%   
Avg P/E ratio x60.536.4 166.1%  
P/CF ratio (eoy) x41.220.0 206.0%  
Price / Book Value ratio x7.94.3 184.0%  
Dividend payout %7.419.1 38.6%   
Avg Mkt Cap Rs m55,69228,083 198.3%   
No. of employees `0000.86.0 13.5%   
Total wages/salary Rs m9052,167 41.8%   
Avg. sales/employee Rs Th15,159.81,817.0 834.3%   
Avg. wages/employee Rs Th1,111.8359.0 309.7%   
Avg. net profit/employee Rs Th1,130.1127.7 885.1%   
INCOME DATA
Net Sales Rs m12,34010,968 112.5%  
Other income Rs m20840 524.9%   
Total revenues Rs m12,54911,007 114.0%   
Gross profit Rs m1,6331,565 104.4%  
Depreciation Rs m431633 68.2%   
Interest Rs m1262 19.6%   
Profit before tax Rs m1,398909 153.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m478139 344.3%   
Profit after tax Rs m920771 119.4%  
Gross profit margin %13.214.3 92.7%  
Effective tax rate %34.215.3 224.1%   
Net profit margin %7.57.0 106.1%  
BALANCE SHEET DATA
Current assets Rs m6,4805,725 113.2%   
Current liabilities Rs m2,4895,454 45.6%   
Net working cap to sales %32.32.5 1,310.4%  
Current ratio x2.61.0 248.1%  
Inventory Days Days7362 116.7%  
Debtors Days Days6672 92.0%  
Net fixed assets Rs m3,0495,307 57.5%   
Share capital Rs m680184 368.9%   
"Free" reserves Rs m6,3436,331 100.2%   
Net worth Rs m7,0236,516 107.8%   
Long term debt Rs m01,323 0.0%   
Total assets Rs m9,78911,970 81.8%  
Interest coverage x115.515.6 738.6%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.30.9 137.6%   
Return on assets %9.57.0 136.9%  
Return on equity %13.111.8 110.7%  
Return on capital %20.112.4 162.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,4674,507 76.9%   
Fx outflow Rs m3,3481,141 293.3%   
Net fx Rs m1193,366 3.5%   
CASH FLOW
From Operations Rs m390886 44.0%  
From Investments Rs m-638-1,706 37.4%  
From Financial Activity Rs m-191,316 -1.4%  
Net Cashflow Rs m-270497 -54.5%  

Share Holding

Indian Promoters % 0.0 59.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 5.5 12.5 44.0%  
FIIs % 6.4 6.0 106.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.2 22.4 58.9%  
Shareholders   49,890 12,805 389.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TIMKEN INDIA With:   NESCO LIMITED  TIL LTD  BAJAJ FINANCE  CREST VENTURES  CCL INTERNATIONAL  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

The BSE HEALTHCARE Index Down 2% ; VIVIMED LABS LTD Among Top Losers (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

The BSE HEALTHCARE Index Down at 16,043 (down 2.0%). Among the top losers in the BSE HEALTHCARE Index today are VIVIMED LABS LTD, LINCOLN PHAR and INDOCO REMEDIES. Meanwhile, the BSE Sensex has plunged 0.7% to 37,489.

TIMKEN INDIA Announces Quarterly Results (1QFY19); Net Profit Up 44.3% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, TIMKEN INDIA has posted a net profit of Rs 316 m (up 44.3% YoY). Sales on the other hand came in at Rs 4 bn (up 20.7% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

Sandhar Technologies IPO: Worth Betting on This Automotive Component Manufacturer? (IPO)

Mar 17, 2018

Should you subscribe to the IPO of Sandhar Technologies Ltd?

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

TIMKEN INDIA Announces Quarterly Results (4QFY18); Net Profit Down 7.8% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, TIMKEN INDIA has posted a net profit of Rs 237 m (down 7.8% YoY). Sales on the other hand came in at Rs 3 bn (up 25.2% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TIMKEN INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK TIMKEN INDIA

  • Track your investment in TIMKEN INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

TIMKEN INDIA 5-YR ANALYSIS

COMPARE TIMKEN INDIA WITH

MARKET STATS